Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Insider sales to satisfy RSU tax withholding reduced Johanna Friedl-Naderer's direct holdings in Dyne Therapeutics (DYN). On 09/04/2025 she reported automatic sales of 894 shares at a weighted average price of $13.27 (transactions ranged $13.08–$13.50) tied to RSUs that vested from a September 3, 2024 grant. On 09/05/2025 she reported automatic sales of 144 shares at $13.41 related to RSUs from a December 4, 2024 grant.
After these transactions her reported beneficial ownership declined from 95,017 to 94,873 shares. The filings state the sales were automatic to satisfy tax withholding and executed under a binding arrangement consistent with a Rule 10b5-1 plan; 74,514 RSUs remain unvested.
Dyne Therapeutics insider sale by Chief Medical Officer Kerr Douglas: On 09/04/2025 and 09/05/2025 Mr. Douglas reported automatic sales of common stock to satisfy tax withholding for vested restricted stock units. A total of 4,425 shares were sold (3,552 shares on 09/04 at a weighted-average price of $13.27 and 873 shares on 09/05 at $13.41). These sales were executed under binding RSU agreements consistent with Rule 10b5-1 affirmative defense and are described as automatic, not discretionary. After the reported transactions the reporting person beneficially owned 88,390 shares, which includes 74,625 unvested RSUs.
Dyne Therapeutics Form 144 summary: This notice reports a proposed sale of 2,640 shares of Dyne common stock through Stifel Nicolaus, with an aggregate market value of $35,404.00 and an approximate sale date of 09/05/2025. The filer acquired 9,081 shares as restricted stock units from the issuer on 09/04/2025 and lists the acquisition payment type as equity compensation. The filing also discloses a prior sale by John Cox of 4,060 shares on 06/05/2025 for gross proceeds of $54,186.00. The company has 142,263,740 shares outstanding, making the proposed sale a very small fraction of total shares. The filer certifies they have no undisclosed material adverse information about the issuer.
Dyne Therapeutics reported a Form 144 notice showing a proposed sale of 4,552 shares of Common Stock on 09/04/2025 through Stifel Nicolaus & Company on Nasdaq with an aggregate market value of $60,402. The shares were acquired as Restricted Stock Units from the issuer on 09/03/2025 (11,875 units) and 09/04/2025 (3,000 units), with payment noted as cash. The filer also disclosed a prior sale of 1,342 shares on 06/05/2025 yielding $17,911. The notice includes the seller's representation that no undisclosed material adverse information is known.
Dyne Therapeutics (Nasdaq: DYN) filed an 8-K stating that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) to its investigational antisense oligonucleotide DYNE-251 for Duchenne muscular dystrophy patients amenable to exon 51 skipping. BTD provides earlier, more frequent FDA interactions and eligibility for priority review, potentially shortening time to market if efficacy and safety are confirmed. The filing furnishes, but does not file, the related press release as Exhibit 99.1 and contains no financial statements, trial data, or updated guidance. Management characterizes the event as material under Regulation FD, signaling strategic importance to Dyne’s pipeline and future revenue prospects, but investors must note that DYNE-251 still requires successful pivotal studies and eventual FDA approval.